FIELD: medicine.
SUBSTANCE: nutraceutical composition is intended for treatment or prevention of adiposity or the conditions bound to adiposity, such as achrestic diabetes (AD, type II) and a syndrome X which includes effective amounts of epigallocatechine gallate (EGCG) and 4 (4-hydroxyphenyl)-2-butanone (KM). Also the method of treatment or prevention of adiposity or the conditions bound to adiposity, such as achrestic diabetes (AD, type II) both a syndrome X and application of EGCG and KM in manufacture of nutraceutical composition is revealed.
EFFECT: synergistic effect at adiposity treatment or prophylaxes.
9 cl, 4 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF BLOOD PRESSURE REDUCTION IN PRE-HYPERTENSIVE INDIVIDUALS AND/OR IN INDIVIDUALS HAVING METABOLIC SYNDROME | 2006 |
|
RU2427382C2 |
| COMPOSITION PROMOTING REGULATION OF TOTAL CHOLESTEROL AND LDL CHOLESTEROL AND/OR WEIGHT LOSS AND/OR THERMOGENESIS | 2008 |
|
RU2465787C1 |
| METHOD OF TREATING OVARIAN CANCER, VERSIONS OF ITS METASTASIS AND RECURRENCE | 2015 |
|
RU2582939C1 |
| COMPOSITION FOR TREATMENT OF OBESITY AND ASSOCIATED METABOLIC SYNDROME | 2005 |
|
RU2334523C2 |
| OVERWEIGHT OR OBESITY REDUCTION | 2007 |
|
RU2443417C2 |
| PHARMACEUTICAL COMBINATION FOR TREATING AND/OR PREVENTING DISORDERS RELATED TO OVERWEIGHT AND/OR OBESITY, AND BASED METHOD OF TREATING | 2014 |
|
RU2552926C1 |
| THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR POTENTIAL DIABETES | 2008 |
|
RU2467743C2 |
| COMPOSITIONS CONTAINING 15-OHEPA AND METHODS OF USING SAME | 2014 |
|
RU2671208C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING OBESITY RELATED DISORDERS, AND METHOD OF TREATING AND/OR PREVENTING OBESITY RELATED DISORDERS | 2013 |
|
RU2561583C2 |
| APPLICATION OF SIBUTRAMIN ANALOGS FOR PREVENTING DIABETES MELLITUS | 1997 |
|
RU2245709C2 |
